Homeland Security Bill — Eli Lilly Man in Bush Cabinet

Homeland Security Bill – Eli Lilly Man in Bush Cabinet Tue, 19 Nov 2002 According to a biography on Competitive Enterprise Institute (CEI), Eli Lilly’s Man in the President’s Cabinet, Mitchell E. Daniels, Jr., sits on both Homeland Security and National Security Councils. Eli Lilly happens to be the defendant…

Investigative series finds kids drugged without cause – Journal News

November 08, 2002 Investigative series finds kids drugged without cause – Journal News The Journal News, a regional NYS newspaper conducted a three month investigation of residential treatment centers (RTC) for troubled children in NYS. The findings reported in a 7-part investigative series show “a pattern of increasing use” of…

Lawsuits & press info RE: SSRI addiction / suicide risk – not scientific literature

Lawsuits & press info RE: SSRI addiction / suicide risk–not scientific literature Fri, 25 Oct To gain knowledge about the scope of a serious threat to public health–i.e., severe adverse drug effects of antidepressant drugs– physicians and consumers must turn to the popular and alternative press, rather than “peer reviewed”…

Bitter Pill for David Healy: academia under pharma influence

Bitter Pill for David Healy: academia under pharma influence May 21, 2002 One wonders how many embarrassing causes celebres are needed before academic institutions take back control of the university from the corrosive influence of the pharmaceutical/ biotech industry? In 2000, Dr. David Healy may have been surprised by the…

Psychiatrist’s Undisclosed Financial Ties Prompt Reproval – NYT

Psychiatrist’s Undisclosed Financial Ties Prompt Reproval – NYT Sun, 3 Aug 2003 The New York Times reports that Dr. Charles Nemeroff, head of psychiatry and behavioral sciences at Emory School of Medicine (Atlanta) has been rebuked by colleagues for failing to disclose his substantial financial ties to drug companies whose…

Dissenting Opinion – Proposed Children’s Workgroup Reinterpretation of Fed Regs 45 CFR 46 sects. 404 & 406

Dissenting Opinion (NHRPAC Children Workgroup) re: Proposed Reinterpretation of Fed. Regs Protecting Children (45 CFR 46, sections 404 and 406) May 14, 2002 To: Alan Fleischman, MD, Chair, Children’s Workgroup of NARPAC        Mary Faith Marshall, Ph.D., Chair, NARPAC From: Vera Hassner Sharav Re: Dissenting Opinion re: Report to NHRPAC, proposing…

Conflicts of Interest in Clinical Trials

Presented by Vera Hassner Sharav
14th Tri-Service Clinical Investigation Symposium
Sponsored by The U.S. Army Medical Department and The Henry M. Jackson Foundation for the Advancment of Military Medicine

The cornerstone of public trust in medical research is the integrity of academic institutions and the expectation that universities, which rely on public funding, have a responsibility to serve the public good. Financial conflicts of interest affect millions of American people – those who are subjects of clinical trials testing new drugs and those who are prescribed drugs after their approval.

Sharav Presentation before US Army Medical Dept., May 6, 2002

CONFLICTS OF INTEREST Presented by Vera Hassner Sharav 14th TRI-SERVICE CLINICAL INVESTIGATION SYMPOSIUM Sponsored By THE U.S. ARMY MEDICAL DEPARTMENT And THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCMENT OF MILITARY MEDICINE May 5-7, 2002 The cornerstone of public trust in medical research is the integrity of academic institutions and…

Protecting Human Subjects in Research: Are Current Safeguards Adequate?

Current federal regulations set no limits on the level of risk that a competent adult may voluntarily choose to undertake for the sake of science. The regulations require prior approval by a review board (IRB) to ensure the research meets scientific and ethical justification, to ensure that the risks and benefits (if any) are fully disclosed to the subject, and that the subject can exercise the right to give or withhold informed consent.

Studies Link Zyprexa to Diabetes & Deaths_Balt Sun

Studies Link Zyprexa to Diabetes & Deaths_Balt Sun Thu, 20 Mar 2003 Eli Lilly’s best selling drug, olanzapine (Zyprexa), originally approved for schizophrenia, then for bi-polar disorder, is prescribed widely. But the drug has been shown to produce early onset diabetes, severe hyperglycemia–and deaths. Adolescents and young adults appear to…